Novartis International AG (NVS: Quote) announced that findings from a pivotal Phase III clinical trial of Bexsero involving 3,630 infants from two months of age showed that the MenB vaccine demonstrated a protective immune response, and has an acceptable safety profile when administered as a three-dose primary series concomitantly with routine vaccines. A robust booster response was observed in toddlers to a fourth dose administered at 12 months, which may contribute to an extended duration of protection.
Upon regulatory approval, Bexsero, an investigational multicomponent meningococcal group B vaccine, will be the first licensed vaccine with the potential to protect against a broad range of strains that cause MenB disease worldwide. The company said the tolerability profile and immunogenicity of Bexsero have been established through a clinical program including data from large Phase II/III clinical trials involving almost 8,000 patients, including infants.
Click here to receive FREE breaking news email alerts for Novartis AG and others in your portfolio
by RTT Staff Writer
For comments and feedback: editorial@rttnews.comBusiness News